Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelonemdaz in Out-of-Hospital Cardiac Arrest (AWAKE)
NCT03651557Phase 2Unknown
- Sponsor
- GNT Pharma
- Start
- Nov 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of salfaprodil in cardiac arrest (SCA) (3 arms), sponsored by GNT Pharma. Primary endpoint: Neuron Specific Enolase Value at Day 3. Status: unknown.
02
Drugs
salfaprodil
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT03651557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651557.